article 3 months old

ABN Amro Morgans Remains Positive On Ventracor

Australia | May 15 2006

By Chris Shaw (Tokyo)

The latest update from VentrAssist heart device company Ventracor (VCR), which showed a combination of a strong financial position and an update in the number of implants it has achieved globally, was enough for ABN Amro Morgans to reinforce its Buy rating. (FN Arena News notes however the broker has a long standing history of being in support of the company).

ABN Amro Morgans has a target price and valuation on the stock of $1.70 and notes the company has $60m in the kitty following its recent rights issue, while it has now achieved the milestone of 50 implants globally.

Another reason for optimism in the broker’s view is the company has completed the recruitment for its upcoming European trial, for which it expects to receive approval in the December half.

At the same time, the company is in discussions with regulators in the US about expanding its trial in that market, suggesting confidence about the overall outcome of the trial and the results to date.

Investors don’t have much to go on in terms of earnings, but the company has indicated it expects to begin showing some revenue growth in the 2007 financial year assuming it receives approval for its European trial. Institutional investors have been happy to enter the stock, as evidenced by the recent rights issue closing oversubscribed.

The stock has traded between $0.80-$1.72 in the past 12 months, its latest closing price of $0.81 well below ABN’s target price.

The FN Arena database shows only two brokers and equity researchers cover the stock, the Buy rating from ABN Amro not matched by the second rating of "Others Preferred".

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.